Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Travere Therapeutics price target lowered to $39 from $46 at Wedbush » 07:24
04/12/21
04/12
07:24
04/12/21
07:24
TVTX

Travere Therapeutics

$25.57 /

+0.32 (+1.27%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico lowered the firm's price target on Travere Therapeutics to $39 from $46 and keeps an Outperform rating on the shares. Chico sees limited impact from Q1 results as investors await more clarity on the sparsentan filing, the analyst says in a research note.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$25.57 /

+0.32 (+1.27%)

TVTX Travere Therapeutics
$25.57 /

+0.32 (+1.27%)

03/02/21 BMO Capital
Travere Therapeutics price target lowered to $43 from $48 at BMO Capital
02/16/21 Barclays
Travere Therapeutics assumed with an Overweight at Barclays
02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
TVTX Travere Therapeutics
$25.57 /

+0.32 (+1.27%)

  • 12
    Feb
TVTX Travere Therapeutics
$25.57 /

+0.32 (+1.27%)

Over a month ago
Recommendations
Travere Therapeutics price target lowered to $43 from $48 at BMO Capital » 09:31
03/02/21
03/02
09:31
03/02/21
09:31
TVTX

Travere Therapeutics

$30.59 /

-0.24 (-0.78%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim lowered the firm's price target on Travere Therapeutics to $43 from $48 but keeps an Outperform rating on the shares. The company's Q4 earnings miss was driven by the $97M acquisition charge for Orphan Technologies, the analyst tells investors in a research note. Kim adds that he sees the Sparsentan opportunity potentially expanding significantly, with positive IgAN PROTECT data in Q3, increasing his U.S peak sale estimate to $2.1B from $1.3B in FSGS alone.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

02/16/21 Barclays
Travere Therapeutics assumed with an Overweight at Barclays
02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

  • 12
    Feb
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

Earnings
Travere Therapeutics reports Q4 adjusted EPS ($2.20), consensus (47c) » 16:14
03/01/21
03/01
16:14
03/01/21
16:14
TVTX

Travere Therapeutics

$30.59 /

-0.24 (-0.78%)

Reports Q4 revenue…

Reports Q4 revenue $50.98M, consensus $51.66M. "In 2020, our organization executed on all of our key objectives despite the challenges of the ongoing pandemic. This resulted in achieving enrollment milestones in our pivotal studies of sparsentan in FSGS and IgAN at or ahead of schedule, diversifying our pipeline with the addition of TVT-058 and serving more patients than ever before with our approved products," said Eric Dube, chief executive officer of Travere Therapeutics. "Led by the interim readouts from our Phase 3 studies of sparsentan, we expect 2021 to be a pivotal year for Travere. We were very pleased to begin the year with the DUPLEX Study in FSGS achieving its pre-specified interim proteinuria endpoint. Reaching this clinical milestone positions us to engage with regulators in pursuit of submissions for accelerated approval as we continue efforts to prepare our organization for the future commercialization of sparsentan, if approved. We are also looking forward to the interim proteinuria assessment from the PROTECT Study in IgAN during the third quarter, which could potentially position us to ultimately deliver sparsentan as a new treatment standard in both FSGS and IgAN."

ShowHide Related Items >><<
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

02/16/21 Barclays
Travere Therapeutics assumed with an Overweight at Barclays
02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

  • 12
    Feb
TVTX Travere Therapeutics
$30.59 /

-0.24 (-0.78%)

Initiation
Travere Therapeutics assumed with an Overweight at Barclays » 06:21
02/16/21
02/16
06:21
02/16/21
06:21
TVTX

Travere Therapeutics

$26.33 /

-1.34 (-4.84%)

Barclays analyst Carter…

Barclays analyst Carter Gould assumed coverage of Travere Therapeutics with an Overweight rating and $40 price target. Recent top-line sparsentan data from the DUPLEX trial was a "transformative event" for the company, representing a "de-risking milestone" in an initial glomerular disease, with encouraging read-through to a second, Gould tells investors in a research note. The analyst sees these data as supportive of approval in initial glomerular disease in 2022.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$26.33 /

-1.34 (-4.84%)

TVTX Travere Therapeutics
$26.33 /

-1.34 (-4.84%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$26.33 /

-1.34 (-4.84%)

  • 12
    Feb
TVTX Travere Therapeutics
$26.33 /

-1.34 (-4.84%)

Syndicate
Travere Therapeutics 6.55M share Secondary priced at $26.75 » 06:28
02/12/21
02/12
06:28
02/12/21
06:28
TVTX

Travere Therapeutics

$27.75 /

-1.23 (-4.24%)

The deal size was…

The deal size was increased to $175.2M in common stock from $150M in common stock. BofA, Jefferies and SVB Leerink acted as joint book running managers for the offering.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

  • 12
    Feb
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/12/21
02/12
04:55
02/12/21
04:55
ABEO

Abeona Therapeutics

$3.36 /

+0.01 (+0.30%)

, AVRO

Avrobio

$16.85 /

+0.05 (+0.30%)

, BMRN

BioMarin

$86.80 /

+1.37 (+1.60%)

, DNLI

Denali Therapeutics

$69.32 /

-4.115 (-5.60%)

, FIXX

Homology Medicines

$13.75 /

-0.24 (-1.72%)

, FOLD

Amicus

$18.73 /

-0.86 (-4.39%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$51.13 /

-0.91 (-1.75%)

, ORPH

Orphazyme

$12.79 /

-0.01 (-0.08%)

, ORTX

Orchard Therapeutics

$8.20 /

-0.07 (-0.85%)

, PASG

Passage Bio

$21.44 /

+1.465 (+7.33%)

, PFE

Pfizer

$34.43 /

-0.31 (-0.89%)

, RARE

Ultragenyx

$162.86 /

-4.38 (-2.62%)

, SGTX

Sigilon Therapeutics

$39.79 /

+1.04 (+2.68%)

, SNY

Sanofi

$47.68 /

-0.375 (-0.78%)

, TAK

Takeda Pharmaceutical

$17.54 /

+0.01 (+0.06%)

, TVTX

Travere Therapeutics

$27.75 /

-1.23 (-4.24%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

02/10/21
Fly Intel: Top five analyst upgrades
02/10/21 Cantor Fitzgerald
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$18.73 /

-0.86 (-4.39%)

02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
02/12/21 JPMorgan
Amicus downgraded to Neutral from Overweight at JPMorgan
01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/10/21 Morgan Stanley
Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
NVTA Invitae
$51.13 /

-0.91 (-1.75%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.43 /

-0.31 (-0.89%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

02/11/21 Piper Sandler
Ultragenyx price target raised to $170 from $165 at Piper Sandler
01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$47.68 /

-0.375 (-0.78%)

02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

  • 12
    Feb
  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/11/21
02/11
04:55
02/11/21
04:55
ABEO

Abeona Therapeutics

$3.35 /

+0.025 (+0.75%)

, AVRO

Avrobio

$16.80 /

-0.88 (-4.98%)

, BMRN

BioMarin

$85.43 /

-0.31 (-0.36%)

, DNLI

Denali Therapeutics

$73.36 /

+0.38 (+0.52%)

, FIXX

Homology Medicines

$14.00 /

-0.36 (-2.51%)

, FOLD

Amicus

$19.59 /

+0.41 (+2.14%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$51.98 /

-0.57 (-1.08%)

, ORPH

Orphazyme

$12.79 /

-0.28 (-2.14%)

, ORTX

Orchard Therapeutics

$8.27 /

-0.09 (-1.08%)

, PASG

Passage Bio

$19.87 /

-0.22 (-1.10%)

, PFE

Pfizer

$34.74 /

-0.22 (-0.63%)

, RARE

Ultragenyx

$167.17 /

-0.19 (-0.11%)

, SGTX

Sigilon Therapeutics

$38.75 /

+0.48 (+1.25%)

, SNY

Sanofi

$48.06 /

-0.815 (-1.67%)

, TAK

Takeda Pharmaceutical

$17.53 /

-0.195 (-1.10%)

, TVTX

Travere Therapeutics

$28.98 /

-0.93 (-3.11%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

02/10/21
Fly Intel: Top five analyst upgrades
02/10/21 Cantor Fitzgerald
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.59 /

+0.41 (+2.14%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/10/21 Morgan Stanley
Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
NVTA Invitae
$51.98 /

-0.57 (-1.08%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.74 /

-0.22 (-0.63%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.06 /

-0.815 (-1.67%)

02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

  • 12
    Feb
  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

Syndicate
Travere Therapeutics annonces $150M common stock offering » 16:03
02/10/21
02/10
16:03
02/10/21
16:03
TVTX

Travere Therapeutics

$29.06 /

-0.85 (-2.84%)

Travere Therapeutics…

Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $150M of its common stock. BofA Securities, Jefferies and SVB Leerink are acting as the joint book-running managers for the offering.

ShowHide Related Items >><<
TVTX Travere Therapeutics
$29.06 /

-0.85 (-2.84%)

TVTX Travere Therapeutics
$29.06 /

-0.85 (-2.84%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$29.06 /

-0.85 (-2.84%)

TVTX Travere Therapeutics
$29.06 /

-0.85 (-2.84%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/10/21
02/10
04:55
02/10/21
04:55
ABEO

Abeona Therapeutics

$3.32 /

-0.05 (-1.48%)

, AVRO

Avrobio

$17.68 /

-1.62 (-8.39%)

, BMRN

BioMarin

$85.63 /

-0.55 (-0.64%)

, DNLI

Denali Therapeutics

$72.98 /

-3.57 (-4.66%)

, FIXX

Homology Medicines

$14.38 /

-0.39 (-2.64%)

, FOLD

Amicus

$19.18 /

-0.7 (-3.52%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$52.55 /

+1.74 (+3.42%)

, ORPH

Orphazyme

$13.07 /

+ (+0.00%)

, ORTX

Orchard Therapeutics

$8.32 /

+1.055 (+14.52%)

, PASG

Passage Bio

$20.12 /

-0.57 (-2.75%)

, PFE

Pfizer

$34.96 /

+0.14 (+0.40%)

, RARE

Ultragenyx

$167.72 /

+1.9 (+1.15%)

, SGTX

Sigilon Therapeutics

$38.27 /

-0.4 (-1.03%)

, SNY

Sanofi

$48.87 /

+0.275 (+0.57%)

, TAK

Takeda Pharmaceutical

$17.73 /

+0.315 (+1.81%)

, TVTX

Travere Therapeutics

$29.91 /

-1.09 (-3.52%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

ORPH Orphazyme
$13.07 /

+ (+0.00%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
11/10/20 Goldman Sachs
Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
11/06/20 H.C. Wainwright
Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.18 /

-0.7 (-3.52%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
10/28/20 Deutsche Bank
Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
NVTA Invitae
$52.55 /

+1.74 (+3.42%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$13.07 /

+ (+0.00%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.96 /

+0.14 (+0.40%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.87 /

+0.275 (+0.57%)

02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORPH Orphazyme
$13.07 /

+ (+0.00%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/09/21
02/09
04:55
02/09/21
04:55
ABEO

Abeona Therapeutics

$3.37 /

+0.78 (+30.12%)

, AVRO

Avrobio

$19.30 /

+2.17 (+12.67%)

, BMRN

BioMarin

$86.19 /

+1.18 (+1.39%)

, DNLI

Denali Therapeutics

$76.96 /

+6.45 (+9.15%)

, FIXX

Homology Medicines

$14.76 /

+0.92 (+6.65%)

, FOLD

Amicus

$19.88 /

-0.21 (-1.05%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$50.81 /

+1.19 (+2.40%)

, ORPH

Orphazyme

$13.07 /

+0.57 (+4.56%)

, ORTX

Orchard Therapeutics

$7.27 /

-0.085 (-1.16%)

, PASG

Passage Bio

$20.69 /

-0.86 (-3.99%)

, PFE

Pfizer

$34.82 /

-0.1 (-0.29%)

, RARE

Ultragenyx

$166.04 /

+4.28 (+2.65%)

, SGTX

Sigilon Therapeutics

$38.70 /

+4.52 (+13.22%)

, SNY

Sanofi

$48.60 /

+0.4 (+0.83%)

, TAK

Takeda Pharmaceutical

$17.42 /

+0.235 (+1.37%)

, TVTX

Travere Therapeutics

$31.00 /

-0.55 (-1.74%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
11/10/20 Goldman Sachs
Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
11/06/20 H.C. Wainwright
Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.88 /

-0.21 (-1.05%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
10/28/20 Deutsche Bank
Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
NVTA Invitae
$50.81 /

+1.19 (+2.40%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.82 /

-0.1 (-0.29%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.60 /

+0.4 (+0.83%)

02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.